Bbi-214 [updated]

| Assay Type | Result | |---------------------|--------------------------------------| | Target inhibition | IC₅₀ = 85 nM | | Cell viability (cancer line e.g., HeLa) | EC₅₀ = 1.2 µM (72h) | | Metabolic stability (human liver microsomes) | t₁/₂ = 45 min | | Plasma protein binding | 87% bound |

BBI-214 leverages the power of , a radioactive isotope known for its strong gamma and beta emissions. In the context of cancer therapy: bbi-214

The keyword primarily refers to a specific preclinical radiopharmaceutical candidate, Pb-214/Bi-214-TCMC-Trastuzumab , which is being investigated for its potential to treat HER2-positive cancers, such as advanced ovarian cancer. such as advanced ovarian cancer.